|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003483,
umls-concept:C0003641,
umls-concept:C0020672,
umls-concept:C0040613,
umls-concept:C0205217,
umls-concept:C0237477,
umls-concept:C0392747,
umls-concept:C0456388,
umls-concept:C0534191,
umls-concept:C0543467,
umls-concept:C1274040,
umls-concept:C1524063
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-11-26
|
|
pubmed:abstractText |
Aprotinin, once used to reduce allogeneic blood product transfusion during cardiac surgery, was withdrawn from the market in late 2007 over concerns of causing increased mortality. This study was undertaken to determine what, if any, the impact of changing antifibrinolytic agents (from aprotinin to tranexamic acid) for deep hypothermic circulatory arrest cases would have on blood bank resource utilization.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1532-8422
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
959-63
|
|
pubmed:meshHeading |
pubmed-meshheading:20430647-Aged,
pubmed-meshheading:20430647-Anticoagulants,
pubmed-meshheading:20430647-Antifibrinolytic Agents,
pubmed-meshheading:20430647-Aorta,
pubmed-meshheading:20430647-Aorta, Thoracic,
pubmed-meshheading:20430647-Aprotinin,
pubmed-meshheading:20430647-Biological Markers,
pubmed-meshheading:20430647-Blood Cell Count,
pubmed-meshheading:20430647-Blood Transfusion,
pubmed-meshheading:20430647-Cardiac Surgical Procedures,
pubmed-meshheading:20430647-Cardiopulmonary Bypass,
pubmed-meshheading:20430647-Circulatory Arrest, Deep Hypothermia Induced,
pubmed-meshheading:20430647-Cohort Studies,
pubmed-meshheading:20430647-Factor VIIa,
pubmed-meshheading:20430647-Female,
pubmed-meshheading:20430647-Hemostasis,
pubmed-meshheading:20430647-Humans,
pubmed-meshheading:20430647-Male,
pubmed-meshheading:20430647-Middle Aged,
pubmed-meshheading:20430647-Predictive Value of Tests,
pubmed-meshheading:20430647-Recombinant Proteins,
pubmed-meshheading:20430647-Retrospective Studies,
pubmed-meshheading:20430647-Tranexamic Acid
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest.
|
|
pubmed:affiliation |
Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA. roman.sniecinski@emory.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
